Mission Statement, Vision, & Core Values (2026) of Changchun BCHT Biotechnology Co.

Step into the strategic heart of Changchun BCHT Biotechnology Co. (688276.SS), a vaccine-focused biopharmaceutical firm founded in 2004 whose portfolio-ranging from varicella and live nasal influenza vaccines to herpes zoster and vero‑cell rabies vaccines-reflects a mission to "Devote Biotech Today, Create Health Tomorrow," while pursuing a global expansion that targeted at least three new international markets by 2024; with approximately 1,274 employees as of June 2025, BCHT pairs quality-driven production and R&D growth (a planned 20% R&D budget increase) with measurable service goals such as a 90% customer satisfaction target and sustainability commitments to cut carbon emissions by 30% by 2025-read on to explore how these mission, vision and core values translate into product strategy, stakeholder value and real-world public health impact.

Changchun BCHT Biotechnology Co. (688276.SS) - Intro

Changchun BCHT Biotechnology Co. (688276.SS), established in 2004 and headquartered in Changchun, China, is a specialized biopharmaceutical enterprise focused on the research, development, production, and sales of human vaccines. The company's portfolio centers on live and cell-culture vaccines and it has been recognized for contributions to public health through vaccine development and distribution. For more on the company background and business model, see Changchun BCHT Biotechnology Co.: History, Ownership, Mission, How It Works & Makes Money.

• Founded: 2004
• Headquarters: Changchun, Jilin Province, China
• Stock Ticker: 688276.SS (Shanghai STAR Market)
• Employees: ~1,274 (as of June 2025)

Mission

• Develop and deliver safe, effective vaccines that prevent infectious disease and protect population health.
• Advance vaccine technology and manufacturing to improve accessibility and quality.
• Create sustainable healthcare value for patients, partners, and shareholders.

Vision

• Be a leading global vaccine company originating from China, recognized for innovation, quality, and reliable supply.
• Expand international presence while maintaining industry-leading standards in vaccine safety and efficacy.

Core Values

• Scientific Integrity - evidence-driven R&D and transparent quality systems.
• Patient Centricity - prioritizing vaccine safety, accessibility, and public-health impact.
• Operational Excellence - continuous improvement in manufacturing, supply chain and regulatory compliance.
• Collaboration - forging partnerships with research institutions, regulatory bodies, and global distributors.
• Sustainability - long-term value creation for stakeholders and responsible public-health stewardship.

Strategic Priorities & Metrics

• Product quality: maintain GMP compliance across production sites and continuous stability improvements for live vaccines.
• Pipeline expansion: prioritize candidates for broader age indications and enhanced formulations (e.g., intranasal flu vaccines).
• Market expansion: increase export penetration into targeted Asia-Pacific, Latin America and select EMENA markets.
• Capacity & supply: scale manufacturing output to meet multi-million dose annual demand for core vaccines while reducing cold-chain loss.
• Stakeholder returns: balance R&D reinvestment with profitability metrics to enhance shareholder value.

Public-Health Impact & Recognition

• Recognized for contributions to vaccine availability in China through established product registrations and distribution networks.
• Active participant in immunization programs with products used in routine and epidemic-response contexts.

Changchun BCHT Biotechnology Co. (688276.SS) - Overview

• Mission focus: proactive R&D to address current health challenges ('Devote Biotech Today').
• Long-term vision: deliver preventive and therapeutic products that contribute to better population health ('Create Health Tomorrow').
• Alignment: portfolio concentrated on prophylactic vaccines and public-health-oriented biologics.
• Continuity: mission unchanged since establishment, informing M&A, partnerships, and pipeline priorities.

• Pipeline prioritization: vaccines and preventive biologics for high-burden infectious diseases and emerging threats.
• Capital allocation: sustained reinvestment in R&D, manufacturing scale-up, and QA/QC to ensure supply security.
• Partnerships: collaborations with academic institutions, public-health agencies, and international distributors to accelerate access.
• Quality and compliance: investments in GMP compliance and regulatory dossiers to support domestic and global distribution.

• Preventive vaccines targeting bacterial and viral pathogens prevalent in China and export markets.
• Adjunct biologics and formulation technologies aimed at improving vaccine efficacy and stability.
• Pipeline candidates focusing on unmet needs and pandemic preparedness to 'create health tomorrow.'

Changchun BCHT Biotechnology Co. (688276.SS) - Mission Statement

• Advance vaccine pipelines with a focus on safety, efficacy and affordability.
• Ensure supply-chain resilience and GMP-compliant manufacturing capacity to meet domestic and international demand.
• Deliver measurable value to patients, healthcare systems and shareholders through sustainable growth.
• Invest in people: recruit, train and retain talent to support scientific excellence and operational excellence.

• Pipeline progression metrics (IND/CTA submissions, clinical milestones, regulatory approvals).
• Manufacturing scale metrics (annual doses produced, batch release yield, capacity utilization).
• Commercial reach (number of countries with registration, distribution partners, export revenue share).
• Sustainability KPIs (energy intensity, emissions per dose, waste reduction initiatives).
• Human capital metrics (training hours, internal promotion rate, employee engagement score).

Changchun BCHT Biotechnology Co. (688276.SS) - Vision Statement

• Commitment to quality: GMP-compliant manufacturing, stringent quality control and continuous product lifecycle monitoring to ensure safety and efficacy.
• Scientific and technological innovation: sustained investment in R&D to advance biologics, recombinant proteins, and cell-culture technologies.
• Transparency and investor communication: regular disclosures, investor relations activities and proactive protection of shareholder rights.
• Environmental sustainability: initiatives to reduce energy use, lower carbon emissions and implement resource-efficient production processes.
• Culture of continuous improvement: employee-driven process optimization, internal innovation programs and performance-based incentives.
• Ethical compliance: adherence to regulatory frameworks (NMPA, GMP, ISO standards) and industry best practices in all operations.

Strategic priorities driving the vision include accelerating R&D pipelines, expanding manufacturing capacity, strengthening commercial channels domestically and internationally, and embedding ESG principles across the organization. The company measures progress using financial KPIs, R&D intensity, product approval milestones, and environmental metrics.

Operational and governance mechanisms that translate core values into practice:

• R&D governance: cross-functional review boards, milestone-based funding, and external scientific advisory committees.
• Quality assurance: layered QA/QC checks, third-party audits, and recall-ready traceability systems.
• Investor engagement: quarterly earnings calls, annual shareholder meetings, and dedicated IR disclosures.
• Environmental programs: energy-efficient equipment upgrades, waste-water treatment improvements, and supplier sustainability assessments.
• Employee empowerment: suggestion systems, internal incubators for process ideas, and continuous training modules.
• Regulatory & ethics framework: compliance teams, internal audits, and mandatory ethics training for all employees.

Key performance indicators tracked regularly:

• Revenue growth rate and gross margin trends.
• Number of new product registrations and clinical milestones achieved annually.
• R&D return on investment and pipeline progression rates.
• ESG metrics: energy consumption per unit of output, waste diversion rate, and workplace safety incidents.
• Shareholder transparency metrics: timeliness of disclosures and IR responsiveness scores.

For an in-depth financial perspective and investor-focused analysis, see: Breaking Down Changchun BCHT Biotechnology Co. Financial Health: Key Insights for Investors